<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">clinvest</journal-id><journal-title-group><journal-title xml:lang="ru">Качественная клиническая практика</journal-title><trans-title-group xml:lang="en"><trans-title>Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2588-0519</issn><issn pub-type="epub">2618-8473</issn><publisher><publisher-name>ООО «Издательство ОКИ</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37489/2588-0519-2022-4-4-12</article-id><article-id custom-type="elpub" pub-id-type="custom">clinvest-634</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL TRIALS</subject></subj-group></article-categories><title-group><article-title>Особенности мотивации добровольцев, участвующих в клиническом исследовании вакцины от COVID-19</article-title><trans-title-group xml:lang="en"><trans-title>Specifics of motivation of volunteers participating in in a clinical trial of the COVID-19 vaccine</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9333-1244</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Белоусова</surname><given-names>Я. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Belousova</surname><given-names>Y. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Белоусова Яна Денисовна, врач - клинический фармаколог, аспирант по специальности «фармакология, клиническая фармакология»</p><p>Калининград</p></bio><bio xml:lang="en"><p>Belousova Yana D., clinical pharmacologist, post-graduate student in the specialty “Pharmacology, clinical pharmacology”</p><p>Kaliningrad</p></bio><email xlink:type="simple">yana-belousova@inbox.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2503-9580</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рафальский</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Rafalsky</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Рафальский Владимир Витальевич, д. м .н, профессор кафедры терапии Высшей школы медицины; директор Центра клинических исследований</p><p>Калининград</p></bio><bio xml:lang="en"><p>Rafalsky Vladimir V., Dr. Sci. (Med.), Professor Department of Therapy, the Graduate School of Medicine; Director of the Clinical Trials Center</p><p>Kaliningrad</p></bio><email xlink:type="simple">v.rafalskiy@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9896-4462</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кислова</surname><given-names>Е. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Kislova</surname><given-names>E. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кислова Елизавета Денисовна, студент 4-го курса направления «Социология управления»</p><p>Калининград</p></bio><bio xml:lang="en"><p>Kislova Elizaveta D., 4th year student of the direction “Sociology of management”</p><p>Kaliningrad</p></bio><email xlink:type="simple">yelizaveta.prasol@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное автономное образовательное учреждение высшего образования «Балтийский федеральный университет имени Иммануила Канта»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Immanuel Kant Baltic Federal University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>01</day><month>03</month><year>2023</year></pub-date><volume>0</volume><issue>4</issue><fpage>4</fpage><lpage>12</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Белоусова Я.Д., Рафальский В.В., Кислова Е.Д., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Белоусова Я.Д., Рафальский В.В., Кислова Е.Д.</copyright-holder><copyright-holder xml:lang="en">Belousova Y.D., Rafalsky V.V., Kislova E.D.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.clinvest.ru/jour/article/view/634">https://www.clinvest.ru/jour/article/view/634</self-uri><abstract><p>Актуальность. Пандемия коронавирусной инфекции способствовала разработке эффективных методов профилактики, с целью замедления распространения вируса. Массовая вакцинация — единственная возможность обезопасить себя от инфекции. Разработка лекарственных средств, в том числе вакцин, сопряжена с проведением клинических исследований (КИ). Проблема проведения КИ — это набор необходимого числа добровольцев. Цель: выявление особенностей мотивации пациентов, участвующих в  КИ вакцин от COVID-19, поскольку это является очень важным медико- социологическим вопросом, требующим более детального изучения. Материалы и методы. Представлены результаты анонимного анкетирования добровольцев, участвующих в КИ вакцины «ЭпиВакКорона». Всего проанализировано 203 анкеты, содержащие 19 вопросов с ответами жителей г. Калининграда в возрасте от 20 до 84 лет. На этапе завершения участия в КИ была получена информация об отношении респондентов к КИ, основных факторах мотивации или демотивации к участию, степени их доверия КИ. Результаты. Эффективным способом для организации рекрутинга пациентов в КИ вакцин является информация, распространённая через работодателя, эффективность использования СМИ была достаточно низкой. Положительными сторонами участия в КИ для добровольцев являлись этические моменты. Отрицательными факторами для участников были риски, связанные с нежелательными реакциями или получением плацебо. Максимальное влияние на решение добровольцев участвовать в КИ оказывали родственники, в меньшей степени—медицинские работники, медийные персоны и учёные. Заключение. Полученные результаты помогут улучшить рекрутинг пациентов, их информированность о КИ и пользе для медицины и общества. Мотивирующие и демотивирующие факторы позволят усовершенствовать процесс набора пациентов.</p></abstract><trans-abstract xml:lang="en"><p>Background. The pandemic coronavirus infection has contributed to the development of effective preventive methods to slow the spread of the virus. Mass vaccination is the only way to protect oneself from infection. The development of drugs, including vaccines, involves clinical trials (CT). The problem of conducting a CT is recruiting the necessary number of volunteers. Goal: to identify specifics of motivation of patients participating in the clinical trial of COVID-19 vaccines, as it is a very important medical and sociological issue requiring more detailed study. Materials and Methods. The results of an anonymous questionnaire survey of volunteers participating in the “EpiVacCorona” vaccine CT are presented. Overall, 203 questionnaires were analyzed, containing 19 questions answered by the residents of Kaliningrad, aged 20 to 84 years. At the stage of completion of participation in the clinical trial, information was obtained about the respondent’s attitudes to the trial, the main factors of motivation or demotivation to participate, the degree of their trust in the trial. Results. Information disseminated through the employer was an effective way to organize patient recruitment for the vaccine CT; the effectiveness of using the media was quite low. The positives of participation in the CT for volunteers were ethical considerations. Negatives for participants were the risks associated with adverse reactions or receiving a placebo. Relatives had the greatest influence on the volunteers’ decision to participate in the CT, and medical professionals, media personalities, and scientists had less influence. Conclusion. The results will help to improve patient recruitment, patient awareness of the CT, and the benefits to medicine and society. Motivating and demotivating factors will improve patient recruitment.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>COVID-19</kwd><kwd>клиническое исследование</kwd><kwd>социологическое исследование</kwd><kwd>вакцина</kwd><kwd>коронавирусная инфекция</kwd><kwd>мотивация участия в клиническом исследовании</kwd></kwd-group><kwd-group xml:lang="en"><kwd>COVID-19</kwd><kwd>clinical trial</kwd><kwd>sociological study</kwd><kwd>vaccine</kwd><kwd>coronavirus infection</kwd><kwd>motivation to participate in a clinical trial</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Gu J, Song J, Wang J, Liu T, Zhan J, Yan W, et al. Stigmatization related COVID-19 and PTSD among Chinese graduates. BMC Psychiatry. 2022;22(1):439. doi:10.1186/s12888-022-04073-0</mixed-citation><mixed-citation xml:lang="en">Gu J, Song J, Wang J, Liu T, Zhan J, Yan W, et al. Stigmatization related COVID-19 and PTSD among Chinese graduates. BMC Psychiatry. 2022;22(1):439. doi:10.1186/s12888-022-04073-0</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Министерство здравоохранения РФ [Электронный ресурс]. (Ministry of Health of the Russian Federation [Internet]. (In Russ).). URL: https://covid19.rosminzdrav.ru/ (дата обращения: 30.06.2022).</mixed-citation><mixed-citation xml:lang="en">Министерство здравоохранения РФ [Электронный ресурс]. (Ministry of Health of the Russian Federation [Internet]. (In Russ).). URL: https://covid19.rosminzdrav.ru/ (дата обращения: 30.06.2022).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Won JH, Lee H. The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic. Int J Mol Sci. 2020;21(24):9775. doi:10.3390/ijms21249775</mixed-citation><mixed-citation xml:lang="en">Won JH, Lee H. The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic. Int J Mol Sci. 2020;21(24):9775. doi:10.3390/ijms21249775</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Lin Y, Hu Z, Zhao Q, Alias H, Danaee M, Wong LP. Understanding COVID-19 vaccine demand and hesitancy: A nationwide online survey in China. PLoS Negl Trop Dis. 2020;14(12):e0008961. doi:10.1371/journal.pntd.0008961</mixed-citation><mixed-citation xml:lang="en">Lin Y, Hu Z, Zhao Q, Alias H, Danaee M, Wong LP. Understanding COVID-19 vaccine demand and hesitancy: A nationwide online survey in China. PLoS Negl Trop Dis. 2020;14(12):e0008961. doi:10.1371/journal.pntd.0008961</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Abdelhafiz AS, Abd ElHafeez S, Khalil MA, Shahrouri M, Alosaim B, Salem RO, et al. Factors Influencing Participation in COVID-19 Clinical Trials: A Multi-National Study. Front Med (Lausanne). 2021;8:608959. doi:10.3389/fmed.2021.608959</mixed-citation><mixed-citation xml:lang="en">Abdelhafiz AS, Abd ElHafeez S, Khalil MA, Shahrouri M, Alosaim B, Salem RO, et al. Factors Influencing Participation in COVID-19 Clinical Trials: A Multi-National Study. Front Med (Lausanne). 2021;8:608959. doi:10.3389/fmed.2021.608959</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Sun S, Lin D, Operario D. Interest in COVID-19 vaccine trials participation among young adults in China: Willingness, reasons for hesitancy, and demographic and psychosocial determinants. Prev Med Rep. 2021;22:101350. doi:10.1016/j.pmedr.2021.101350</mixed-citation><mixed-citation xml:lang="en">Sun S, Lin D, Operario D. Interest in COVID-19 vaccine trials participation among young adults in China: Willingness, reasons for hesitancy, and demographic and psychosocial determinants. Prev Med Rep. 2021;22:101350. doi:10.1016/j.pmedr.2021.101350</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Calina D, Hartung T, Docea AO, Spandidos DA, Egorov AM, Shtil man MI, et al. COVID-19 vaccines: ethical framework concerning human challenge studies. Daru. 2020;28(2):807-12. doi:10.1007/s40199-020-00371-8</mixed-citation><mixed-citation xml:lang="en">Calina D, Hartung T, Docea AO, Spandidos DA, Egorov AM, Shtil man MI, et al. COVID-19 vaccines: ethical framework concerning human challenge studies. Daru. 2020;28(2):807-12. doi:10.1007/s40199-020-00371-8</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Lim HX, Arip M, Yahaya AAA, Jazayeri SD, Poppema S, Poh CL. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials. Front Biosci (Landmark Ed). 2021;26(11):1286-304. doi:10.52586/5024</mixed-citation><mixed-citation xml:lang="en">Lim HX, Arip M, Yahaya AAA, Jazayeri SD, Poppema S, Poh CL. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials. Front Biosci (Landmark Ed). 2021;26(11):1286-304. doi:10.52586/5024</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Elshammaa K, Hamza N, Elkholy E, Mahrous A, Elnaem M, Elrggal M. Knowledge, attitude, and perception of public about participation in COVID-19 clinical trials: A study from Egypt and Saudi Arabia. Saudi Pharm J. 2022;30(3):283-90. doi:10.1016/j.jsps.2022.01.008</mixed-citation><mixed-citation xml:lang="en">Elshammaa K, Hamza N, Elkholy E, Mahrous A, Elnaem M, Elrggal M. Knowledge, attitude, and perception of public about participation in COVID-19 clinical trials: A study from Egypt and Saudi Arabia. Saudi Pharm J. 2022;30(3):283-90. doi:10.1016/j.jsps.2022.01.008</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Anand U, Jakhmola S, Indari O, Jha HC, Chen ZS, Tripathi V, et al. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/ COVID-19 Pandemic Management: A Review on the Recent Update. Front Immunol. 2021;12:658519. doi:10.3389/fimmu.2021.658519</mixed-citation><mixed-citation xml:lang="en">Anand U, Jakhmola S, Indari O, Jha HC, Chen ZS, Tripathi V, et al. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/ COVID-19 Pandemic Management: A Review on the Recent Update. Front Immunol. 2021;12:658519. doi:10.3389/fimmu.2021.658519</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Sharma O, Sultan AA, Ding H, Triggle CR. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Front Immunol. 2020;11:585354. doi:10.3389/fimmu.2020.585354</mixed-citation><mixed-citation xml:lang="en">Sharma O, Sultan AA, Ding H, Triggle CR. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Front Immunol. 2020;11:585354. doi:10.3389/fimmu.2020.585354</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Steel R, Buchak L, Eyal N. Why continuing uncertainties are no reason to postpone challenge trials for coronavirus vaccines. J Med Ethics. 2020;46(12):808-12. doi:10.1136/medethics-2020-106501</mixed-citation><mixed-citation xml:lang="en">Steel R, Buchak L, Eyal N. Why continuing uncertainties are no reason to postpone challenge trials for coronavirus vaccines. J Med Ethics. 2020;46(12):808-12. doi:10.1136/medethics-2020-106501</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Noirmain C, Gil-Wey B, Pichon I, Brindel P, Haller G. Factors associated with patient willingness to participate in anaesthesia clinical trials: a vignette-based cross-sectional study. BMC Med Res Methodol. 2020;20(1):67. doi:10.1186/s12874-020-00949-5</mixed-citation><mixed-citation xml:lang="en">Noirmain C, Gil-Wey B, Pichon I, Brindel P, Haller G. Factors associated with patient willingness to participate in anaesthesia clinical trials: a vignette-based cross-sectional study. BMC Med Res Methodol. 2020;20(1):67. doi:10.1186/s12874-020-00949-5</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ehde DM, Roberts MK, Humbert AT, Herring TE, Alschuler KN. COVID-19 vaccine hesitancy in adults with multiple sclerosis in the United States: A follow up survey during the initial vaccine rollout in 2021. Mult Scler Relat Disord. 2021;54:103163. doi:10.1016/j.msard.2021.103163</mixed-citation><mixed-citation xml:lang="en">Ehde DM, Roberts MK, Humbert AT, Herring TE, Alschuler KN. COVID-19 vaccine hesitancy in adults with multiple sclerosis in the United States: A follow up survey during the initial vaccine rollout in 2021. Mult Scler Relat Disord. 2021;54:103163. doi:10.1016/j.msard.2021.103163</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Walters SJ, Bonacho Dos Anjos Henriques-Cadby I, Bortolami O, Flight L, Hind D, Jacques RM, et al. Recruitment and retention of participants in randomised controlled trials: a review of trials funded and published by the United Kingdom Health Technology Assessment Programme. BMJ Open. 2017;7(3):e015276. doi:10.1136/bmjopen-2016-015276</mixed-citation><mixed-citation xml:lang="en">Walters SJ, Bonacho Dos Anjos Henriques-Cadby I, Bortolami O, Flight L, Hind D, Jacques RM, et al. Recruitment and retention of participants in randomised controlled trials: a review of trials funded and published by the United Kingdom Health Technology Assessment Programme. BMJ Open. 2017;7(3):e015276. doi:10.1136/bmjopen-2016-015276</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Abu-Farha RK, Alzoubi KH, Khabour OF. Public Willingness to Participate in COVID-19 Vaccine Clinical Trials: A Study from Jordan. Patient Prefer Adherence. 2020;14:2451-8. doi:10.2147/ppa.S284385</mixed-citation><mixed-citation xml:lang="en">Abu-Farha RK, Alzoubi KH, Khabour OF. Public Willingness to Participate in COVID-19 Vaccine Clinical Trials: A Study from Jordan. Patient Prefer Adherence. 2020;14:2451-8. doi:10.2147/ppa.S284385</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Wu H, Ward M, Brown A, Blackwell E, Umer A. COVID-19 Vaccine intent in appalachian patients with multiple sclerosis. Mult Scler Relat Disord. 2022;57:103450. doi:10.1016/j.msard.2021.103450</mixed-citation><mixed-citation xml:lang="en">Wu H, Ward M, Brown A, Blackwell E, Umer A. COVID-19 Vaccine intent in appalachian patients with multiple sclerosis. Mult Scler Relat Disord. 2022;57:103450. doi:10.1016/j.msard.2021.103450</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Purvis RS, Willis DE, Moore R, Bogulski C, McElfi sh PA. Perceptions of adult Arkansans regarding trusted sources of information about the COVID-19 pandemic. BMC Public Health. 2021;21(1):2306. doi:10.1186/s12889-021-12385-1</mixed-citation><mixed-citation xml:lang="en">Purvis RS, Willis DE, Moore R, Bogulski C, McElfi sh PA. Perceptions of adult Arkansans regarding trusted sources of information about the COVID-19 pandemic. BMC Public Health. 2021;21(1):2306. doi:10.1186/s12889-021-12385-1</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2021;27(2):225-8. doi:10.1038/s41591-020-1124-9</mixed-citation><mixed-citation xml:lang="en">Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2021;27(2):225-8. doi:10.1038/s41591-020-1124-9</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Detoc M, Bruel S, Frappe P, Tardy B, Botelho-Nevers E, GagneuxBrunon A. Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic. Vaccine. 2020;38(45):7002-6. doi:10.1016/j.vaccine.2020.09.041</mixed-citation><mixed-citation xml:lang="en">Detoc M, Bruel S, Frappe P, Tardy B, Botelho-Nevers E, GagneuxBrunon A. Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic. Vaccine. 2020;38(45):7002-6. doi:10.1016/j.vaccine.2020.09.041</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
